Puma Biotechnologies is walking back some bullish prognostications for its breast cancer treatment, delaying its planned FDA submission by as much as a year and lending weight to some creeping doubts about its top prospect.

…read more

Source: Puma tanks on a fresh setback for its breast cancer drug


0 No comments